• Mechanism

    HDAC inhibitor (topical)

  • Disease areas

    Cutaneous T-cell lymphoma (MF)

    Basal cell carcinoma

Remetinostat - for the treatment of cutaneous T-cell lymphoma (mycosis fungoides)

MF cutaneous T-cell lymphoma (CTCL) is a rare form of blood cancer that shows up first in the skin. A key unmet medical need for patients in early-stages of MF-CTCL is efficacy on cancerous skin lesions and the symptom of significant itching.



MF-CTCL affects around 20,000 people in each of the US and Europe and approximately 75 percent of patients are in early stages (1).

In its early stages, the disease is confined to the skin and is not immediately life threatening. Patients do however experience a reduction in quality of life due to disfiguring lesions and disease symptoms, mainly significant itching.

Patients also suffer an increased risk of infections as the protective skin barrier is no longer intact. Existing treatments do not sufficiently address the patient need. Thus, patients are in need of an efficacious but also highly tolerable treatment, since the early stages of disease may last for many years.

  1. Source: Leukemia & Lymphoma Society.

Market potential


In the US alone, 15,000 patients with early stage MF-CTCL represents a total market potential of USD 900 million.


A novel HDAC inhibitor for topical use

Medivir is developing remetinostat as a topical application for use in early stage MF-CTCL. Remetinostat is a histone deacetylase (HDAC) inhibitor. HDAC inhibitors are approved for treatment of MF-CTCL in late-stage patients but are not recommended for early-stage patients due to their significant side effects. The unique design of remetinostat enables topical application, making it active only in the skin. As soon as it reaches the blood stream, it is degraded, avoiding the side effects associated with other HDAC inhibitors.


Promising data paves way for a phase III study in MF-CTCL

In the phase II study, remetinostat demonstrated efficacy on skin lesions, reduction of itching and high tolerability in patients with early-stage MF-CTCL. This positive top-line data showed that patients that were given the highest dose in the study (remetinostat gel 1% twice daily) had the highest proportion of confirmed responses (40 percent, 8 patients out of 20). In addition, 80 percent of the patients in this dose group who had clinically significant itching at baseline experienced a meaningful reduction in the severity of their itching. Remetinostat was well-tolerated and without signs of systemic adverse effects in the study.

Remetinostat has been granted Orphan Drug Designation (ODD) in the US. In December 2018, Medivir had clarifying and positive discussions with FDA about the design of the phase III program for MF-CTCL. One successful phase III study is expected to be sufficient for market approval as treatment for patients with early-stage MF-CTCL. Medivir intends to seek a partner for the continued development and commercialization of remetinostat.


Phase II study in basal cell carcinoma

In a recently completed investigator-initiated study in collaboration with researchers at Stanford University, remetinostat was given to patients with basal cell cancer (BCC). The preliminary results indicate that remetinostat has potential as an effective and well-tolerated treatment of local skin tumors in BCC patients. A publication of final data is now being prepared.


Phase II study in patients with squamous cell carcinoma

At Stanford University, an investigator-initiated phase II clinical trial has been conducted in which remetinostat was given to patients with squamous cell carcinoma (SCC). Four patients with five cutaneous SCCs were included in this case series and treated with remetinostat gel 1%. All five tumours, including a range of histological subtypes, demonstrated complete clinical and pathological resolution after up to 8 weeks of treatment. All patients experienced a localized cutaneous reaction in response to the treatment, which required one patient to discontinue therapy. No systemic adverse events were reported. The results have been published on Further details of the study can be found at, reference number NCT03875859.

Projects from our team


Nucleotide DNA polymerase inhibitor (oral)


SMAC mimetic (intravenous)


Cathepsin K inhibitor (oral)